Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma: A Randomized Phase III Study of the EORTC Melanoma Group.
Latest Information Update: 06 May 2022
At a glance
- Drugs Temozolomide (Primary) ; Dacarbazine
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 07 Jul 2009 Actual end date (25 May 2007) identified as reported by United Kingdom Clinical Research Network.
- 20 Jan 2009 New source identified and integrated (United Kingdom Clinical Research Network).
- 21 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov